Publication Year: 2021 Read Wiley Online Library
Scientists at Eli Lilly were characterizing circulatory inflammatory profiles and underlying systemic disease heterogeneity within atopic dermatitis (AD) patients. The multiplexing study of several pro-inflammatory mediators distinguished between baseline disease severities, demonstrated by greater EASI, SCORAD Index, Itch NRS and DLQI scores. DropArray Technology provided a 5uL- sample volume workflow, which complies towards extended cytokine clusters and comparisons. With sample miniaturization, the performance is capable of depicting an output of scaled and centralized cytokine data per marker across donors. This process led to finding baseline cytokines or chemokines (e.g. Th2/Th22-related biomarkers ) that offer objective and consistent outcome measures of disease severity.